https://orcid.org/0000-0002-0494-0767
References
- Monreal M. Fatal pulmonary embolism or bleeding in patients with venous thromboembolism: implications of real-life data. Thromb Res. 2019;181(Suppl 1):S6–S9. 31477230
- Jiménez D, Bikdeli B, Quezada A, et al; RIETE Investigators. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ. 2019;366:l4416. doi:10.1136/bmj.l441631358508
- Hlavacek P, Guo JD, Rosenblatt L, et al. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin. 2019;35(12):2043–2051. doi:10.1080/03007995.2019.165306731387467
- Ageno W, Turpie AG. Low-molecular-weight heparin in the treatment of pulmonary embolism. Semin Vasc Surg. 2000;13(3):189–193.11005462
- Giorgi-Pierfranceschi M, Di Micco P, Cattabiani C, et al; RIETE Investigators. Platelet count and major bleeding in patients receiving vitamin K antagonists for acute venous thromboembolism, findings from real world clinical practice. Medicine (Baltimore). 2015;94(47):e1915. doi:10.1097/MD.000000000000191526632687
- Yan Y-D, Zhang C, Shen L, et al. Net clinical benefit of non-vitamin K antagonist oral anticoagulants for venous thromboembolism prophylaxis in patients with cancer: a systematic review and trade-off analysis from 9 randomized controlled trials. Front Pharmacol. 2018;9:575. doi:10.3389/fphar.2018.0057529946255
- Rosenberg DJ, Press A, Fishbein J, et al. External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. Thromb Haemost. 2016;116(3):530–536. doi:10.1160/TH16-01-000327307054
- Piovella C, Dalla Valle F, Trujillo-Santos J, et al; RIETE Investigators. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. Intern Emerg Med. 2014;9(8):847–852. doi:10.1007/s11739-014-1073-824839226
- Nieto JA, Solano R, Trapero Iglesias N, et al; RIETE Investigators. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb Res. 2013;132(2):175–179. doi:10.1016/j.thromres.2013.06.01923849097
- Fauchier L, Chaize G, Gaudin A-F, Vainchtock A, Rushton-Smith SK, Cotté F-E. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol. 2016;217:85–91. doi:10.1016/j.ijcard.2016.04.17327179213
- Di Micco P, Ruiz-Giménez N, Nieto JA, et al; RIETE Investigators. Platelet count and outcome in patients with acute venous thromboembolism. Thromb Haemost. 2013;110(5):1025–1034. doi:10.1160/TH13-04-035223925476
- Di Micco P, Fontanella A, Falvo N, et al; RIETE Investigators. Natural history of patients developing thrombocytopenia while receiving anticoagulant therapy for venous thromboembolism. Int Angiol. 2012;31(1):92–95.22330631